The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) closed the day trading at $21.85 down -0.59% from the previous closing price of $21.98. In other words, the price has decreased by -$0.59 from its previous closing price. On the day, 0.73 million shares were traded. RCKT stock price reached its highest trading level at $22.34 during the session, while it also had its lowest trading level at $21.6.
Ratios:
For a better understanding of RCKT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.80 and its Current Ratio is at 7.80. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on April 02, 2024, initiated with a Neutral rating and assigned the stock a target price of $39.
On October 24, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $65.
On February 01, 2023, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $45.Morgan Stanley initiated its Overweight rating on February 01, 2023, with a $45 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 22 ’24 when Militello John sold 833 shares for $22.87 per share. The transaction valued at 19,051 led to the insider holds 54,406 shares of the business.
SOUTHWELL DAVID P sold 10,000 shares of RCKT for $240,520 on Apr 15 ’24. The Director now owns 114,784 shares after completing the transaction at $24.05 per share. On Apr 12 ’24, another insider, SOUTHWELL DAVID P, who serves as the Director of the company, sold 70,000 shares for $24.36 each. As a result, the insider received 1,705,265 and left with 95,160 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCKT now has a Market Capitalization of 1989283072 and an Enterprise Value of 1629384832.
Stock Price History:
The Beta on a monthly basis for RCKT is 1.10, which has changed by 0.23866212 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, RCKT has reached a high of $32.53, while it has fallen to a 52-week low of $14.89. The 50-Day Moving Average of the stock is -17.89%, while the 200-Day Moving Average is calculated to be -5.34%.
Shares Statistics:
Over the past 3-months, RCKT traded about 728.06K shares per day on average, while over the past 10 days, RCKT traded about 754790 shares per day. A total of 90.28M shares are outstanding, with a floating share count of 83.98M. Insiders hold about 7.21% of the company’s shares, while institutions hold 96.47% stake in the company. Shares short for RCKT as of 1713139200 were 11004215 with a Short Ratio of 15.11, compared to 1710460800 on 10243884. Therefore, it implies a Short% of Shares Outstanding of 11004215 and a Short% of Float of 15.840000000000002.
Earnings Estimates
The stock of Rocket Pharmaceuticals Inc (RCKT) is currently in the spotlight, with 12.0 analysts actively rating and assessing its market standing.On average, analysts expect EPS of -$0.68 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$0.83, while EPS last year was -$0.73. The consensus estimate for the next quarter is -$0.7, with high estimates of -$0.49 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1.49 and -$3.38 for the fiscal current year, implying an average EPS of -$2.65. EPS for the following year is -$1.84, with 13.0 analysts recommending between -$0.1 and -$3.17.
Revenue Estimates
Based on 11 analysts’ estimates, the company’s revenue will be $163.27M in the next fiscal year. The high estimate is $325.82M and the low estimate is $23.1M.
